How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Table 1 Urinary tract infections after botulinum toxin injections in contemporary series

Ref.	Type of toxin	Patients	sUTI before injections	sUTI after injection	P	Bacteriuria % (n)	Symptomatic and asymptomatic UTI after injections	P
Gamé et al[19], 2008	Botox	30	1.79/pp/6 mo	0.2/pp/6 mo	0.003	43
	300 UI	15 MS
		14 SCI
		1 Myelitis
Giannantoni et al[9],	Botox	17 SCI	6.7/pp/yr	1.8/pp/yr	0.001
2009	300 UI
Cruz et al[20], 2011	Placebo	154 MS					Placeb: 32%	P < 0.05
	Botox						200 UI: 58%	(vs placebo)
	200 UI						300 UI: 70%
	300 UI
Cruz et al[20], 2011	Placebo	121 SCI					Placebo: 50%
	Botox						200 UI: 52.6%
	200 UI						300 UI: 56.4%
	300 UI
Kuo et al[22], 2011	Botox	33 SCI		6.80%		28 (37)
	200 UI
Herschorn et al[23], 2011	Placebo	57					Placebo: 55%
	Botox	38 SCI					300 UI: 57%
	300 UI	19 MS
Ginsberg et al[21],	Placebo	227 MS					Placebo: 28%
2012	Botox						200 UI: 51%
	200 UI						300 UI: 50%
	300 UI
Ginsberg et al[21],	Placebo	189 SCI					Placebo: 42%
2012	Botox						200 UI: 48%
	200 UI						300 UI: 50%
	300 UI
Jia et al[24], 2013	Botox	SCI 41	1.49/pp/6 mo	0.78/pp/6 mo
	300 UI

sUTIs: Symptomatic urinary tract infections; SCI: Spinal cord injury.